Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;25(9):2665-2678.
doi: 10.1007/s12094-023-03203-8. Epub 2023 May 6.

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022)

Jose Angel Garcia-Saenz #  1 , Isabel Blancas #  2 , Isabel Echavarria #  3 , Carmen Hinojo #  4 , Mireia Margeli #  5 , Fernando Moreno #  6 , Sonia Pernas #  7 , Teresa Ramon Y Cajal #  8 , Nuria Ribelles #  9 , Meritxell Bellet #  10
Affiliations

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022)

Jose Angel Garcia-Saenz et al. Clin Transl Oncol. 2023 Sep.

Erratum in

Abstract

Advanced breast cancer represents a challenge for patients and for physicians due its dynamic genomic changes yielding to a resistance to treatments. The main goal is to improve quality of live and survival of the patients through the most appropriate subsequent therapies based on the knowledge of the natural history of the disease. In these guidelines, we summarize current evidence and available therapies for the medical management of advanced breast cancer.

Keywords: ABC; ADC; Advanced breast cancer; Anti-HER2 therapy; Endocrine therapy; Guidelines; IOT.

PubMed Disclaimer

Conflict of interest statement

JAG-S reports Advisory Board and Speaker from Novartis, Lilly, Daiichi Sankyo, Gilead; Advisory Board from AstraZeneca, Pierre Fabre, EISAI; Grant from Seagen; Speaker from Roche, Asofarma and Exact Sciences and Advisory Board and Grant from Stemline Menarini. IBL-B reports Advisory Board, Speaker and Grant from Roche, Lilly and Astrazeneca; Advisory Board and Speaker from Novartis, Celgene, Eisai, Pierre Fabre, BMS, Daiichi Sankyo, Grünenthal, Seagen and Veracyte and Grant from Agendia. IE reports Advisory Board and Speaker from Lilly, Speaker from Pfizer, Novartis; Advisory Board from AstraZeneca; Speaker from Roche and Pierre Fabre. MMV reports Advisory Board from Gilead, Lilly Piere Fabre Daichy Eisai; Grant from Pfizer and Speaker from Pierre Fabre. FMA reports Advisory Board, Speaker, Grant and others from Pfizer; Advisory Board from Novartis, Daiichi Sankyo, Astra Zeneca; Others from MSD, Pierre Fabre, Gilead, Seagen and Roche. SP reports Advisory Board, Speaker and Non-financial Support from AstraZeneca and Daiichi; Advisory Board and Grant from Roche; Speaker and Non-financial Support from Lilly and Novartis; Advisory Board from Pierre Fabre and Seagen; Non-financial Support from Gilead; Advisory Board and Non-financial Support from Pfizer and Speaker from Eisai. MBE reports Speaker from Pfizer, Lilly, Novartis; Advisory Board from Pfizer, Lilly, Novartis and Stemline Menarini and Travel Expenses from Pfizer. CH, TRC, and NR have nothing to disclose.

Figures

Fig. 1
Fig. 1
Algorithm proposal for decision-making on the treatment of patients with ABC
Fig. 2
Fig. 2
Algorithm advanced ER+/HER2- breast cancer
Fig. 3
Fig. 3
Algorithm advanced TNBC. (*) T-Dxd could be considered if patient is not suitable for sacituzumab govitecan. sacituzumab govitecan) is also preferred as second line if patient has received a previous neo/adjuvant chemotherapy schedule
Fig. 4
Fig. 4
Algorithm for first-line advanced HER2+ breast cancer
See this image and copyright information in PMC

References

    1. SEOM: Las Cifras Del Cáncer En España. 2022. available at: https://seom.org/images/LAS_CIFRAS_DEL_CANCER_EN_ESPANA_2022.pdf
    1. Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision medicine Working Group. Ann Oncol. 2020;31:1491–1505. doi: 10.1016/j.annonc.2020.07.014. - DOI - PubMed
    1. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929–1940. doi: 10.1056/NEJMoa1813904. - DOI - PubMed
    1. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475–1495. doi: 10.1016/j.annonc.2021.09.019. - DOI - PubMed
    1. Hildebrandt MG, Naghavi-Behzad M, Vogsen M. A role of FDG-PET/CT for response evaluation in metastatic breast cancer? Semin Nucl Med. 2022;52:520–530. doi: 10.1053/j.semnuclmed.2022.03.004. - DOI - PubMed

LinkOut - more resources